The PLUSS Trial

Intratracheal budesonide + surfactant to ⬆️ survival free of BPD in extremely preterm infants | @nhmrc @MCRI_for_kids @chiesigroup @thrasherfund

[The PLUSS Trial @PlussTrial]

Today the results of the @PlussTrial were published in @JAMA_current!

Intratracheal budesonide mixed with surfactant to increase survival free of BPD in extremely preterm infants born <28 weeks’ gestation

https://t.co/hRD0SpQDLV

A thread 🧵 (1/X) #neotwitter

[Brett J. Manley 🤷🏼‍♂️ @drbretty]

The BiB trial from the US of intratracheal budesonide mixed with surf is published, and confirms the results of the @PlussTrial #neotwitter

[Clinical Epi & Biostatistics Unit (CEBU) @CEBU_Melbourne]

Huge congratulations to the @PlussTrial team and our amazing statisticians, Kate Francis and Susan Donath, for their double win at the @ACTA_org Trial of the Year Awards! 🎉The ACTA STInG Excellence in Statistics Award recognizes their commitment to rigorous trial methodologies.

[The PLUSS Trial @PlussTrial]

Today the @PlussTrial was awarded the @ACTA_org Clinical Trial of the Year!!!

As always the first people to thank are the incredible families and babies of who took part in the trial 🙏🏻

And of course thanks and congratulations to the entire @PlussTrial team!

#neoTwitter

[Brian King @BrianKingNeo]

The most recent @AAPneonatal Journal Club webinar is available - https://t.co/UZ1ZhjHbIj
Dr. Aung (Neonatal-Perinatal Fellow, St. Christopher's Hospital) gave an excellent overview of the PLUSS trial. Thank you to @drbretty and Dr. Watterberg for joining! #neotwitter @NeoTECaN

[The PLUSS Trial @PlussTrial]

Steroid and surfactant mix fails to impact bronchopulmonary dysplasia in preterm infants https://t.co/TyWrHb6h8L

[The PLUSS Trial @PlussTrial]

Early Intratracheal Budesonide Didn't Improve Outcomes for Preterm Infants | MedPage Today https://t.co/ry4XgJ1b26

[The PLUSS Trial @PlussTrial]

Today the results of the @PlussTrial were published in @JAMA_current!

Intratracheal budesonide mixed with surfactant to increase survival free of BPD in extremely preterm infants born <28 weeks’ gestation

https://t.co/hRD0SpQDLV

A thread 🧵 (1/X) #neotwitter

[The PLUSS Trial @PlussTrial]

Link to Editorial of the @PlussTrial results by Erik Jensen @ChildrensPhila:

https://t.co/NNXo37QluK

[JAMA @JAMA_current]

In extremely preterm infants receiving surfactant, early intratracheal budesonide may have little to no effect on survival free of bronchopulmonary dysplasia. @PlussTrial

https://t.co/ltHT2bb78n

[Brett J. Manley 🤷🏼‍♂️ @drbretty]

Wonderful commentary by ⁦@NeonatalResearc⁩ on the context and results of the ⁦@PlussTrial⁩! #neotwitter https://t.co/N2MvuGguB1

[Brett J. Manley 🤷🏼‍♂️ @drbretty]

The @PlussTrial was published today:

[NICU Lived Network @NICULived]

Did your baby participate? Published today in @JAMA_current - the results of The @PlussTrial!

21 NICUs in 4 countries - Australia, New Zealand, Canada & Singapore - enrolled just over 1060 babies.

@drbretty joins us!

WATCH THE FULL EPISODE --> https://t.co/uIerQzhUaX

[The PLUSS Trial @PlussTrial]

Link to Editorial of the @PlussTrial results by Erik Jensen @ChildrensPhila:

https://t.co/NNXo37QluK

[The PLUSS Trial @PlussTrial]

Link to podcast interview 🎙️ with @TracyALieu (@JAMA_current deputy editor) about the @plusstrial results:

https://t.co/TvuamrNOlj

[The PLUSS Trial @PlussTrial]

Thanks go first and foremost to the amazing babies and their families that participated in the @plusstrial! 🙏🏻

And to the sponsor @MCRI_for_kids and funders incl. @nhmrc and @ChiesiGroup

And of course to the wonderful group of investigators who made it all happen!

(13/END)

[The PLUSS Trial @PlussTrial]

We powered the @PlussTrial to find a 10% increase in the primary outcome of survival free of BPD at 36w PMA: from 50% to 60%

We needed 1038 infants and we aimed for 1060

The trial recruited in 21 tertiary NICUs in 4 countries (mainly 🇦🇺 & 🇳🇿, 1 centre in 🇸🇬 and 1 in 🇨🇦)

(6/X)

[The PLUSS Trial @PlussTrial]

So, disappointingly 😔, the @PlussTrial found that intratracheal budesonide mixed with surfactant had little or no effect on survival free of BPD in EPTIs…

Longer term outcomes are important and we are currently assessing participants at 2 years of age (PLUSS2)

(12/X)